



OPEN ACCESS

ORIGINAL ARTICLE

Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial

Harald T Jorstad,¹ Clemens von Birgelen,² A Marco W Alings,³ Anho Liem,⁴ Jan Melle van Dantzig,⁵ Wybren Jaarsma,⁶ Dirk J A Lok,⁷ Hans J A Kragten,⁸ Keesjan de Vries,⁹ Paul A R de Milliano,¹⁰ Adrie J A M Withagen,¹¹ Wilma J M Scholte op Reimer,¹ Jan G P Tijssen,¹ Ron J G Peters¹

For numbered affiliations see end of article.

Correspondence to

Harald Thune Jørstad, Department of Cardiology, Academic Medical Center—University of Amsterdam, Meibergdreef 9, P.O. Box 22660, Room F3-241, Amsterdam 1100 DD, The Netherlands; h.t.jorstad@amc.uva.nl

Received 17 March 2013

Revised 30 May 2013

Accepted 31 May 2013

Published Online First

28 June 2013

ABSTRACT

Objective To quantify the impact of a practical, hospital-based nurse-coordinated prevention programme on cardiovascular risk, integrated into the routine clinical care of patients discharged after an acute coronary syndrome, as compared with usual care only.

Design RESPONSE (Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists) was a randomised clinical trial.

Setting Multicentre trial in secondary and tertiary healthcare settings.

Participants 754 patients admitted for acute coronary syndrome.

Intervention A nurse-coordinated prevention programme, consisting of four outpatient nurse clinic visits, focusing on healthy lifestyles, biometric risk factors and medication adherence, in addition to usual care.

Main outcome measures The main outcome was 10-year cardiovascular mortality risk as estimated by Systematic Coronary Risk Evaluation at 12 months follow-up. Secondary outcomes included Framingham Coronary Risk Score at 12 months, in addition to changes in individual risk factors. Risk factor control was classified as 'poor' if 0 to 3 factors were on target, 'fair' if 4 to 6 factors were on target, and 'good' if 7 to 9 were on target.

Results The mean Systematic Coronary Risk Evaluation at 12 months was 4.4 per cent (SD 4.5) in the intervention group and 5.4 per cent (SD 6.2) in the control group ($p=0.021$), representing a 17.4% relative risk reduction. At 12 months, risk factor control classified as 'good' was achieved in 35% of patients in the intervention group compared with 25% in the control group ($p=0.003$). Attendance to the nurse-coordinated prevention programme was 92%. In the intervention group, 86 rehospitalisations were observed against 132 in the control group (relative risk reduction 34.8%, $p=0.023$).

Conclusions The nurse-coordinated hospital-based prevention programme in addition to usual care is a practical, yet effective method for reduction of cardiovascular risk in patients with coronary disease. Our data suggest that the counselling component of the programme may lead to a reduction in hospital readmissions.

Trial Registration trialregister.nl Identifier TC1290.

INTRODUCTION

Patients with established coronary artery disease (CAD) are at high risk of recurrent coronary events and mortality. Effective secondary prevention can reduce this risk, and comprehensive guidelines for the long-term management of patients with CAD have been issued by the American Heart Association/American College of Cardiology,¹ and the European Society of Cardiology.²

At present, a considerable gap exists between these guidelines and their implementation in clinical practice.³ Nurse-coordinated prevention programmes may contribute to better achievement of preventive targets. Previous trials evaluating such initiatives have been performed in primary care, or have included complex multidisciplinary interventions.^{4–6} We designed the Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists (RESPONSE) trial to quantify the impact of a practical, hospital-based nurse-coordinated prevention programme integrated into the routine clinical care of patients who have sustained an acute coronary syndrome (ACS).

METHODS

Design

RESPONSE is a multicentre, randomised clinical trial that was conducted in 11 centres in The Netherlands. Detailed study methods have been published elsewhere and are summarised here.⁷ The protocol was approved by the institutional committees on human research of all recruiting hospitals.

Trial participants

Patients aged 18–80 years were eligible if they had been diagnosed with an ACS (ST segment elevation myocardial infarction, non-ST segment elevation myocardial infarction or unstable angina pectoris), within 8 weeks prior to entry into the study. Patients were ineligible if they met any of the following exclusion criteria: visits to the nurse-coordinated prevention programmes not feasible; not available for follow-up; surgery, percutaneous coronary intervention or other interventions expected within 8 weeks after inclusion; limited life



Open Access
Scan to access more
free content

To cite: Jorstad HT, von Birgelen C, Alings AMW, et al. *Heart* 2013;**99**: 1421–1430.

expectancy (≤ 2 years); previously enrolled in the nurse-coordinated prevention programme; New York Heart Association class III or class IV heart failure.

Recruitment and randomisation

Written informed consent was obtained during or shortly after hospitalisation. Patients were subsequently randomised to either the nurse-coordinated prevention programme in addition to usual care (intervention group) or usual care alone (control group). The online randomisation protocol consisted of a pre-generated block-stratified randomisation protocol (<http://www.responsestudie.nl>). Study personnel entered patient's initials, date of birth and gender, and participating individuals were assigned a study identification number along with their allocation to either the intervention group or control group.⁷ All patients were informed about the subject of the study, that is, secondary prevention of coronary disease. However, in order to reduce a potential Hawthorne-effect,^{8,9} we did not disclose the fact that patients were randomised to the nurse-coordinated prevention programme or usual care only.⁷ At the end of the trial, all information about the actual randomisation was provided to all patients. The institutional committees on human research explicitly approved this process of providing limited trial information to patients. The randomly assigned treatment of patients was not disclosed to treating cardiologists or general practitioners.

Usual care included outpatient clinic visits to treating cardiologists and other relevant specialists. This included referral to cardiovascular rehabilitation according to the national guidelines on cardiovascular rehabilitation.¹⁰ In short, cardiovascular rehabilitation typically consisted of a 12 week programme of evaluation of physical, psychological and social functioning, of providing education, physical exercise, and interventions to improve physical and social functioning and to improve cardiovascular risk factors and/or risk behaviour.¹⁰ Cardiologists were encouraged, in all patients, to adhere to current national and international guidelines for secondary prevention of cardiovascular disease.

Nurse-coordinated prevention programme

The programme included four outpatient clinic visits to a cardiovascular nurse during the first 6 months after inclusion: at weeks 2, 7, 12 and 17 after baseline. The nurse-coordinated prevention programme followed a protocol based on national and international guidelines, focusing on (1) healthy lifestyles, (2) biometric risk factors and (3) medication adherence.^{1,2,11} The nine targets for the nurse-coordinated prevention programme are presented in box 1.

During each visit, smoking status, dietary status, level of physical exercise, weight, waist circumference, blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose and HbA1c were reviewed. Nurses provided general lifestyle advice, including dietary advice. Nurses provided specific educational material and individual counselling to achieve smoking cessation, adequate physical exercise and healthy weight/fat distribution. In collaboration with the responsible specialist, treatment of blood pressure and lipid levels was adjusted to achieve the target levels described in box 1. This included titration of medication by the nurse or referral to other health professionals as needed. Patients with suspected, undiagnosed diabetes or diabetes with inadequate glucometabolic control were referred to their treating physician. Adherence to prescribed medication was encouraged at each visit, including antithrombotic therapy and a statin. If discontinued, reasons for discontinuation were documented, and if

Box 1 Targets for nurse-coordinated prevention programme¹¹

Lifestyle and biometric targets

Smoking

1. Not smoking

Anthropometry

2. Body mass index $< 25 \text{ kg/m}^2$
3. Waist circumference: for women $\leq 80 \text{ cm}$, for men $\leq 94 \text{ cm}$

Blood pressure

4. Systolic blood pressure $< 140 \text{ mm Hg}$

Blood cholesterol

5. LDL cholesterol concentration $\leq 2.5 \text{ mmol/L}$

Physical activity

6. ≥ 30 min of moderate intensity physical activity 5 times a week

Diet

7. Vegetable consumption ≥ 200 grams daily
8. Fruit consumption ≥ 2 pieces daily
9. Alcohol consumption: for women ≤ 2 units per day, for men ≤ 3 units per day

Medication adherence

Secondary cardiovascular preventive drug management

Preventive cardiovascular medications are prescribed as clinically indicated by responsible specialist or general practitioner, at doses used in usual care for all patients with coronary heart disease.

- ▶ Antiplatelet drugs
- ▶ B-blockers
- ▶ ACE inhibitors or angiotensin-II receptor blockers
- ▶ Lipid-lowering drugs (statins)
- ▶ Diuretics

possible the therapy was restarted. Between 6 months (end of the programme) and 12 months follow-up, there were no visits to the nurse-coordinated prevention programme.

Nurses contributing to the prevention programme were registered nurses with a 4-year bachelor's degree and experience in the care of cardiac patients ($n=15$ in 11 centers). They were selected by the local investigators and received at least one day of central training in cardiovascular risk management and 1 day of local individual training in using the study protocol in addition to investigators meetings. All nurses were given a 3-day course in motivational interviewing at the Department of Medical Psychology, Academic Medical Center in Amsterdam, the Netherlands. To assess their ability to deliver the intervention, individual nurses were observed on at least two separate occasions by study personnel. Video recordings were made of the nurses' consultations (with patients' permission) that were evaluated by a medical psychologist, who gave feedback to individual nurses.

Follow-up and data collection

We collected data at baseline, and at 6 months and 12 months follow-up. We recorded gender, educational status, work status,

civil status, ethnicity, stress status, cardiovascular history, smoking status prior to index event, dietary status, levels of physical exercise, medication, weight, height, waist circumference and blood pressure. Blood pressure was measured using a validated automated sphygmomanometer. Blood samples were analysed by the local laboratories for the measurements of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose and HbA1c. Patients were instructed to observe a period of 8 h of fasting prior to blood sampling. We recorded data on all hospital readmissions in 12 months follow-up, including visits to the cardiology emergency room and visits to the outpatient clinic of treating cardiologists. All data at baseline, 6 months and 12 months were collected by independent research personnel not involved in the execution of the nurse-coordinated prevention programme.

Outcomes

The impact of the intervention was quantified by the proportion of risk factors on target and by changes in individual risk factors. To estimate the overall impact on cardiovascular risk, we used Systematic Coronary Risk Evaluation (SCORE) as an integrated measure. SCORE estimates the 10 years risk (per cent) of cardiovascular death based on age, gender, total cholesterol, systolic blood pressure and smoking status. (The original trial protocol specifies the Copenhagen risk score as the primary outcome, which was replaced by SCORE after the Copenhagen

investigators refused to share the algorithm). For all SCORE calculations, we used age at baseline. We did not correct for the fact that SCORE was developed in populations without previous cardiovascular events. The primary outcome of the study was SCORE at 12 months follow-up, that is, at least 6 months after the last visit to the nurse, in order to include potential late loss of treatment effect.¹²

Secondary outcomes included Framingham Coronary Risk Score (FCRS) at 12 months,¹³ in addition to changes in individual risk factors. All of the above risk indicators at 6 months were analysed as secondary outcomes. The control of risk factors was classified as 'poor' if 0 to 3 factors were on target, 'fair' if 4 to 6 factors were on target, and 'good' if 7 to 9 were on target. Patients qualified for a diagnosis of diabetes mellitus if a minimum two measurements of fasting glucose were >7.0 mmol/L or if one measurement was >11.0 mmol/L regardless of fasting status, or if 1 HbA1c measurement was $>6.5\%$.

Cumulative numbers of hospital readmissions in 12 months were classified according to diagnosis by treating cardiologists: readmission for ACS, other cardiac readmissions (chest pain no ACS, atrial fibrillation, congestive heart failure and cerebrovascular accident) and elective readmissions.

Statistical methods

The primary outcome (SCORE) was compared between the two groups using a student two-sample t test. For secondary outcomes,




Figure 1 Trial profile.

means, SD and 95%-confidence intervals (95% CI) were used to describe continuous variables; frequencies and percentages were used to describe categorical variables. Comparisons between groups were summarised as proportion (percentage) mean change (SD) and number, and independent samples t-tests, χ^2 or Fisher's exact tests, Yates-Cochran and McNemar tests were applied. We used SPSS statistics V.18 for all statistical analyses.

With 754 patients in two groups, the study has more than 80% power to detect a difference of 1 point in SCORE function at 12 months between the two treatment groups, assuming a SD of 4.5 points.

RESULTS

Figure 1 presents the trial profile. Between June 2006 and July 2009 1666 patients were screened for study enrolment, whereof 1243 met eligibility criteria, and 754 provided consent and were randomised. In the intervention group, nine patients did not receive the intervention as randomised, and five patients did not complete follow-up (three died and two had early discontinuation of intervention). In the control group, 12 patients were excluded from the study and 18 patients did not complete follow-up (10 died, 1 lost to follow-up, 7 did not complete follow-up). Of 710 patients attending 12 months follow-up,

14 patients had incomplete outcome data and 696 patients (92%) were included in the primary outcome analysis. The mean number of visits to the nurse-coordinated prevention programme was 3.8, and 335/366 (92%) of patients attended the maximum of all four visits.

Table 1 presents baseline patient characteristics. Patients had a mean age of 58 years and 80% were men. The majority of patients had no previous vascular history (73%). The index event was ST elevation myocardial infarction in 49%, a non-ST elevation myocardial infarction in 33% and unstable angina pectoris in 18%. Coronary revascularisation after the index event was performed in 79% of patients.

Table 2 presents the proportions of patients with risk factors on target. At 12 months, more patients in the intervention group versus the control group were on target for systolic blood pressure (264 (75%) vs 211 (61%), $p < 0.001$), LDL cholesterol (263 (74%) vs 222 (64%), $p = 0.007$), physical activity (239 (66%) vs 192 (52%), $p < 0.001$), vegetable consumption (286 (80%) vs 244 (70%), $p = 0.02$) and fruit consumption (332 (93%) vs 292 (84%) $p < 0.001$). The prevalence of smoking significantly decreased in both groups, without any difference at 12 months between the two groups (83 (23%) vs 85 (25%), $p = 0.72$). There was no difference between intervention and

Table 1 Patient characteristics by treatment group

	No. (%) of Patients*			
	Nurse-coordinated prevention programme (N=366)		Usual care (N=367)	
Age (years), mean (SD)	57.5	(9.9)	57.8	(10.4)
Female, n (%)	73	(20%)	74	(20%)
Diagnostic category at index event				
STEMI, n (%)	181	(50%)	174	(48%)
NSTEMI, n (%)	120	(33%)	120	(33%)
Unstable angina pectoris, n (%)	55	(17%)	73	(19%)
Therapeutic intervention for index event				
No revascularisation, n (%)	71	(19%)	79	(22%)
Percutaneous coronary intervention, n (%)	282	(78%)	271	(75%)
Coronary artery bypass surgery, n (%)	20	(6%)	22	(6%)
Previous vascular disease (prior to index event)				
Myocardial infarction, n (%)	60	(16%)	65	(18%)
Percutaneous coronary intervention, n (%)	46	(13%)	55	(15%)
Coronary artery bypass surgery, n (%)	19	(5%)	19	(5%)
Stroke, n (%)	14	(4%)	10	(3%)
Peripheral artery disease, n (%)	20	(6%)	23	(6%)
Congestive heart failure, n (%)	3	(1%)	3	(1%)
No known previous vascular disease, n (%)	269	(74%)	266	(73%)
History of cardiovascular risk factors, n (%)				
Positive family history, n (%)	219	(60%)	220	(60%)
Diagnosed diabetes mellitus, n (%)	49	(13%)	52	(14%)
Dyslipidaemia, n (%)	254	(69%)	263	(72%)
Current smoking, n (%)†	169	(46%)	156	(43%)
Ex-smoker, n (%)	134	(37%)	143	(39%)
Hypertension, n (%)	142	(39%)	130	(36%)
Educational				
Fewer than 8 years, n (%)	51	(14%)	47	(13%)
College or university, n (%)	76	(21%)	74	(20%)

Data are n (%) or mean (SD).

*Unless otherwise indicated. Percentages may not sum to 100 because of rounding.

†Smoking status prior to index event.

NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; UAP, unstable angina pectoris.

Table 2 Number of risk factors on target by treatment group

	Baseline		6 months follow-up		12 months follow-up		Within group		Between group	
	Nurse group (n=366)	Usual care (n=367)	Nurse group (n=358)	Usual care (n=352)	Nurse group (n=359)	Usual care (n=348)	Nurse group Baseline—12 months p Value	Usual care Baseline—12 months p Value	6 months p Value	12 months p Value
Body mass index ≤ 25 kg/m ² , n (%)	84 (23%)	105 (29%)	75 (21%)	88 (25%)	77 (21%)	94 (27%)	0.90	0.28	0.21	0.09
Waist circumference men ≤ 94 cm, women ≤ 80 cm, n (%)	75 (21%)	99 (27%)	88 (25%)	90 (26%)	82 (23%)	87 (25%)	0.28	0.29	0.86	0.54
Systolic blood pressure ≤ 140 mm Hg, n (%)	248 (68%)	267 (73%)	256 (72%)	228 (65%)	264 (75%)	211 (61%)	0.02	<0.001	0.05	<0.001
LDL cholesterol ≤ 2.5 mmol/L, n (%)	247 (68%)	247 (68%)	284 (80%)	241 (69%)	263 (74%)	222 (64%)	0.073	0.11	0.001	0.007
Current smoker*, n (%)	169 (46%)	156 (43%)	77 (22%)	72 (21%)	83 (23%)	85 (25%)	<0.001	<0.001	0.78	0.72
Physical activity ≥ 30 min, ≥ 5 times per week, n (%)	185 (51%)	185 (50%)	257 (70%)	202 (55%)	239 (66%)	192 (52%)	<0.001	0.60	<0.001	<0.001
Alcohol consumption men ≤ 3 units per day, women ≤ 2 units per day, n (%)	347 (95%)	340 (93%)	346 (97%)	336 (95%)	346 (97%)	331 (95%)	0.02	0.004	0.27	0.35
Vegetables ≥ 200 g per day, n (%)	260 (71%)	243 (66%)	283 (80%)	250 (71%)	286 (80%)	244 (70%)	<0.001	0.10	0.02	0.007
Fruit ≥ 2 pieces per day, n (%)	292 (80%)	307 (84%)	337 (95%)	303 (86%)	332 (93%)	292 (84%)	<0.001	0.58	<0.001	<0.001
Other parameters										
Triglyceride ≤ 2.0 mmol/L, n (%)	291 (80%)	291 (80%)	287 (80%)	280 (80%)	277 (78%)	279 (81%)	0.052	0.80	0.93	0.41
HDL cholesterol ≥ 1.0 mmol/L, n (%)	212 (58%)	207 (57%)	242 (68%)	233 (67%)	243 (69%)	237 (69%)	<0.001	<0.001	0.75	0.99
Diastolic blood pressure ≤ 90 mmHg, n (%)	313 (86%)	319 (87%)	310 (87%)	291 (83%)	297 (84%)	276 (80%)	0.73	0.005	0.14	0.14
Total cholesterol ≤ 4.5 mmol/L, n (%)	257 (70%)	255 (70%)	280 (78%)	247 (70%)	254 (71%)	251 (73%)	0.93	0.67	0.02	0.74

Data are n (%).

*Number of patients currently smoking, data presented at baseline represents smoking status prior to index event.

Table 3 Risk factor change at 6 months and 12 months by treatment group

	Value at baseline		Change at 6 months		Change 12 months		6 months p Value	12 months p Value
	Nurse group (n=366)	Usual care (n=367)	Nurse group (n=357)	Usual care (n=352)	Nurse group (n=359)	Usual care (n=348)		
Weight, kg (SD)	87.2 (15.7)	84.2 (14.3)	0.05 (7.3)	0.3 (7.8)	-0.5 (11.3)	0.2 (10.6)	0.62	0.38
Body mass index, kg/m ² (SD)	28.3 (4.4)	27.4 (4.0)	0.03 (2.4)	0.1 (2.5)	-0.2 (4.2)	0.03 (3.3)	0.72	0.38
Waist circumference, cm (SD)	100.4 (13.6)	98.6 (13.0)	-1.3 (13.2)	0.2 (10.2)	-1.9 (13.6)	0.2 (14.3)	0.1	0.048
Systolic blood pressure, mm Hg (SD)	132.7 (21.3)	131.5 (19.8)	-0.8 (18.5)	2.7 (18.9)	-0.1 (17.1)	4.2 (18.9)	0.014	0.002
Diastolic blood pressure, mm Hg (SD)	79.1 (11.5)	78.6 (11.3)	1.2 (11.4)	2.6 (12.4)	1.9 (11.1)	3.0 (11.4)	0.01	0.20
Total cholesterol, mmol/L (SD)	4.1 (1.0)	4.1 (1.0)	-0.1 (1.1)	0.03 (0.9)	-0.01 (1.2)	0.02 (1.0)	0.076	0.71
LDL cholesterol, mmol/L (SD)	2.2 (0.9)	2.3 (0.8)	-0.1 (1.0)	-0.05 (0.9)	-0.1 (1.0)	0.03 (0.8)	0.21	0.16
HDL cholesterol, mmol/L (SD)	1.1 (0.3)	1.1 (0.4)	0.1 (0.3)	0.03 (0.5)	0.1 (0.4)	0.02 (0.5)	0.22	0.16
Triglyceride, mmol/L (SD)	1.6 (1.4)	1.5 (0.8)	-0.1 (1.1)	-0.003 (0.8)	-0.01 (0.9)	-0.03 (0.8)	0.22	0.71

Data are mean (SD).

control group in body mass index (BMI) and waist circumference at 12 months. In the intervention group, an increase was observed in the number of patients on target at 12-months follow-up as compared with baseline for systolic blood pressure (248 (68%) to 264 (75%), $p=0.02$), physical activity (185 (51%) to 139 (66%), $p<0.001$) and vegetable consumption (260 (71%) to 286 (80%), $p<0.001$). Conversely, in the control group, risk factor control deteriorated for systolic blood pressure (267 (73%) to 211 (61%), $p<0.001$), and remained unchanged for physical activity (185 (50%) to 192 (52%), $p=0.60$) and vegetable consumption (243 (66%) to 244 (70%), $p=0.10$).

Table 3 presents mean risk factor levels at baseline and changes at 6 months and 12 months. Weight, BMI and waist circumference decreased slightly in the intervention group while remaining unchanged in the control group in 12 months (weight -0.5 (SD 11.3) vs 0.2 (SD 10.6), $p=0.38$, BMI -0.2 (SD 4.2) vs 0.03 (SD 3.3), $p=0.38$, waist circumference -1.9 cm (SD 13.6) vs 0.2 cm (SD 14.3), $p=0.048$). Systolic blood pressure remained unchanged in the intervention group, while an increase was observed in the control group (-0.1 mm Hg (SD 17.1) vs 4.2 mm Hg (SD 18.9), $p=0.002$ for difference in change).

Figure 2 presents the results of the primary outcome of the study. The SCORE cardiovascular 10-year mortality risk at baseline was 5.3 per cent (SD 6.5) in the intervention group and 5.2 per cent (SD 5.5) in the control group ($p=0.74$). At 6 months follow-up, SCORE was 4.4 per cent (SD 4.8) in the intervention group and 5.0 per cent (SD 5.5) in the control group ($p=0.12$), corresponding with an absolute reduction of 0.96 per cent ($p<0.001$) in the intervention group and an absolute reduction of 0.19 per cent ($p=0.47$) in the control group. At 12 months, SCORE was 4.4 per cent (SD 4.5) in the intervention group and 5.4 per cent (SD 6.2) in the control group ($p=0.021$), amounting to an absolute reduction of 0.93 per cent relative to baseline in the intervention group ($p<0.001$) and an increase of 0.17 per cent ($p=0.38$) in the control group. The difference in SCORE between the intervention and control group at 12 months represents a 17.4% reduction in estimated 10-year cardiovascular mortality.

The results of the FCRS were consistent with those of SCORE. At baseline, FCRS was 8.5 per cent (SD 5.7) in the intervention group and 8.1 per cent (SD 5.5) in the control group ($p=0.31$). At 6 months, FCRS was 6.9 per cent (SD 5.0) in the intervention group and 7.4 per cent (SD 5.0) in the control group ($p=0.17$). At 12 months, FCRS was 7.0 per cent (SD 5.2) in the

intervention group and 8.0 per cent (SD 5.7) in the control group ($p=0.017$). This amounts to an absolute reduction of 1.5 per cent relative to baseline in the intervention group ($p<0.001$), and a decrease of 0.05 per cent in the control group ($p=0.78$). The difference in FCRS between the intervention group and control group at 12 months represents a 12.5% reduction in 10-year incidence of coronary mortality and morbidity.

Figure 3 presents the classification of patients according to the number of risk factors on target. At 12 months, risk factor control was classified as ‘good’ in 128 (35%) patients in the intervention group compared with 91 (25%) in the control group ($p=0.003$).

Diabetes mellitus was diagnosed in 9 patients in the intervention group compared with 10 patients in the control group ($p=0.99$). Based on measurements at follow-up visits, an additional 23 patients in the intervention group and 25 patients in the control group ($p=0.77$) qualified for the diagnosis of diabetes mellitus. However, treating physicians did not establish a formal diagnosis of diabetes mellitus in any of these patients.

Table 4 presents the cumulative number of readmissions in 12 months. In total, there were 86 rehospitalisations in the




Figure 2 SCORE cardiovascular mortality estimation. SCORE at baseline, 6 months and 12 months. Error bars show 95% CIs. ACS=acute coronary syndrome.




Figure 3 Classification of achievement of risk factor targets per patient (%). Poor control is classified as 0–3 risk factors, fair control is classified as 4–6 risk factors and good control is classified as 7–9 risk factors on target. Risk factors are smoking, body-mass index <25 kg/m², waist circumference for women ≤80 cm, waist circumference for men ≤94 cm, systolic blood pressure <140 mm Hg, LDL cholesterol ≤2.5 mmol/L, physical activity ≥30 min ≥5 times per week, vegetable consumption ≥200 grams daily, fruit consumption ≥2 pieces daily, alcohol consumption for women ≤2 units per day, alcohol consumption for men ≤3 units per day.

intervention group against 132 in the control group ($p=0.023$). This difference was driven by a 67% reduction in readmissions for non-ACS chest pain (12 admissions vs 36 admissions, $p<0.001$). Cardiology emergency room visits occurred less frequently in the intervention group (29 visits vs 51 visits, $p=0.036$), while cardiology outpatient visits were slightly more common (822 visits vs 778 visits, $p=0.20$). Readmissions for ACS and elective interventions were comparable in both groups.

Table 5 presents adherence to preventive cardiovascular medication. The use of antithrombotic agents and lipid lowering agents was high in both groups. The majority of patients used blood pressure lowering medication. In the intervention group diuretics (76 (21%) vs 53(15%), $p=0.04$) and ACE inhibitors (201 (57%) vs 160 (46%), $p=0.005$) were more frequently prescribed.

DISCUSSION

The main finding of our study is that a practical, hospital-based nurse-coordinated prevention programme on top of usual care leads to a reduction in cardiovascular risk. This was observed

using two different risk functions (SCORE and the FCRS) and a classification of patients according to the number of risk factors that were on target, including self-reported parameters of lifestyle. Moreover, we observed a decrease of in the number of rehospitalisations in the first 12 months for non-ACS chest pain, and fewer visits to the cardiac emergency room in patients attending the nurse-coordinated prevention programme.

The significant improvements in lifestyle parameters that were observed in the intervention group are not reflected in the SCORE or Framingham risk functions. The overall impact of the intervention may therefore be underestimated. The on-target analysis offers an alternative quantification of benefit, as it includes parameters on lifestyle. Compared with usual care alone, the intervention led to a 37% increase in the proportion of patients that was classified as having ‘good’ control of risk factors. This risk reduction was achieved against a background of a high level of usual care, with risk factor levels more favourable than those reported in the literature and with excellent adherence to medication.³ Although our study design included a specific feature to prevent Hawthorne effects, we cannot

Table 4 Hospital readmissions, cardiac emergency room visits and cardiology outpatient visits

	Total (n=710)	Nurse group (n=361)	Usual care (n=349)	p Value
Total number of readmissions	218	86 (39%)	132 (61%)	0.023
Readmissions for ACS	38	17 (45%)	21 (55%)	0.58
STEMI	12	4 (33%)	8 (67%)	0.35
NSTEMI	8	4 (50%)	4 (50%)	0.99
UAP	18	9 (50%)	9 (50%)	0.98
Other CVD readmissions	82	21 (26%)	61 (74%)	<0.001
Chest pain no ACS	48	12 (25%)	36 (75%)	0.001
Atrial fibrillation	9	2 (22%)	7 (78%)	0.09
Congestive HF	6	0 (0%)	6 (100%)	0.034
CVA	3	1 (33%)	2 (67%)	0.57
Others	16	6 (38%)	10 (63%)	0.40
Interventions	29	12 (41%)	17 (59%)	0.41
CAG	6	2 (33%)	4 (67%)	0.42
PCI	21	9 (43%)	12 (57%)	0.54
CABG	2	1 (50%)	1 (50%)	0.99
Elective interventions	98	48 (49%)	50 (51%)	0.68
CAG	61	32 (52%)	29 (48%)	0.67
PCI	26	12 (46%)	14 (54%)	0.74
CABG	11	4 (36%)	7 (64%)	0.37
Cardiac emergency room visits	80	29 (36%)	51 (64%)	0.036
Outpatient cardiology visits	1600	822 (51%)	778 (49%)	0.20

Data are numbers of admissions, interventions or visits (%) as applicable. ACS, acute coronary syndrome; CABG, coronary artery bypass surgery; CAG, coronary angiography; CVA, cerebrovascular accident; CVD, cardiovascular disease; HF, heart failure; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary interventions; STEMI, ST segment elevation myocardial infarction; UAP, unstable angina pectoris.

exclude the possibility that the level of care in the control group has been positively influenced by participation in the trial. This could lead to an underestimation of the effects of the intervention. Compared with our control group, a sample of European patients had lower proportions of patients achieving risk factor targets, particularly in blood pressure control, total cholesterol, and use of lipid lowering therapy and blood pressure lowering agents.³

The multinational EuroAction study showed results similar to our study.⁵ However, EuroAction included a complex, multidisciplinary intervention, while our study investigated the impact of a nursing intervention that is practical, feasible and integrated into routine clinical care. Consistent with our findings, Murchie and colleagues reported that nurse led prevention clinics in general practices in the UK improved medical and lifestyle components of secondary prevention.⁴ Our nurse-coordinated prevention programme took place in a hospital setting and, by comparison, we included younger patients (58 years vs 66 years) with a more recent coronary event. The optimal combination of intervention components, including content, mode of delivery, frequency and duration remains undetermined according to a recent meta-analysis.⁶ A more intensive intervention with more frequent visits could potentially further improve risk factor control, especially in complex patients, but this needs to be assessed in future studies. Our study adds to the existing evidence that a 6 months nurse-coordinated prevention programme, that can be easily implemented, leads to an overall decrease in cardiovascular risk that is sustained at 1 year after an ACS.

The observed difference in hospital readmissions for non-ACS chest pain and visits to the cardiac emergency ward was not anticipated. It may reflect the effectiveness of the counselling component of the nurse programme in preventing unnecessary hospital readmissions and emergency-room visits. However, this was a non-prespecified secondary outcome and this observation requires independent confirmation.

Ideally, the impact of a preventive intervention would be quantified at the level of individual mortality risk. For secondary prevention, individual predictors have been described.^{14 15} However, these observations are based on short-term outcomes and, more importantly, no risk function is currently available that integrates all predictors into an overall estimation of cardiovascular mortality risk. For lack of a validated risk function in secondary prevention, we selected the SCORE function for 10-year cardiovascular risk as the primary outcome in our secondary prevention trial. A recently published, comparable trial has similarly used a primary prevention risk score as the main outcome measure to quantify the effect of a secondary prevention programme.¹⁶ Although the absolute estimates of the SCORE function are inaccurate in secondary prevention, the difference in SCORE between the two groups provides an estimate of the relative overall impact of a risk factor intervention. Our analysis suggests a 17.4% relative risk reduction compared with usual care alone.

Table 5 Secondary cardiovascular preventive medication by treatment group

	Baseline		6 months follow-up		12 months follow-up		6 months p Value	12 months p Value
	Nurse group (n=366)	Usual care (n=367)	Nurse group (n=358)	Usual care (n=352)	Nurse group (n=355)	Usual care (n=348)		
Any antithrombotic agent*, n (%)	363 (99%)	363 (99%)	354 (99%)	354 (99%)	348 (98%)	342 (98%)	0.99	0.99
Any lipid lowering agent†, n (%)	350 (96%)	352 (96%)	345 (96%)	337 (96%)	331 (93%)	328 (94%)	0.70	0.64
β Blockers, n (%)	328 (90%)	326 (89%)	296 (83%)	285 (81%)	270 (76%)	272 (78%)	0.56	0.53
Calcium channel blocker, n (%)	65 (18%)	65 (18%)	82 (23%)	58 (17%)	77 (22%)	65 (19%)	0.04	0.35
Diuretics, n (%)	52 (14%)	52 (15%)	74 (21%)	53 (15%)	76 (21%)	53 (15%)	0.06	0.04
ACE inhibitors, n (%)	200 (55%)	175 (48%)	209 (58%)	162 (46%)	201 (57%)	160 (46%)	0.001	0.005
Angiotensin II receptor blockers, n (%)	36 (10%)	32 (9%)	56 (16%)	49 (14%)	58 (16%)	55 (16%)	0.53	0.92
α Blockers, n (%)	0 (0%)	3 (1%)	0 (0%)	4 (1%)	0 (0%)	4 (1%)	0.06	0.06

Data are n (%). *Antithrombotic agents are aspirine, clopidogrel, dipyridamol or any oral anticoagulant. †Lipid lowering agents are statins or non-statin lipid lowering agents.

Although these results are encouraging, there is room for improvement. Weight loss was insufficient in both groups, in spite of an increase in self-reported adequate physical exercise and improved food choices. However, the intervention group had a mean decrease in waist circumference of 1.9 cm, whereas the control group had an increase of 0.2 cm, potentially reflecting the effects of lifestyle changes. The large number of smokers who quit in both groups could potentially have been a factor limiting weight loss. The slightly higher weight in the intervention group at follow-up may be explained by the higher weight at baseline and the slightly higher proportion of patients who quit smoking. Given the encouraging results in the pharmacological components of the programme, the most important opportunities for further improvement are found in lifestyle parameters. In particular, there is an unmet need for strategies for weight loss and smoking cessation.

Attendance to the nurse-coordinated prevention programme for the four visits in the first 6 months of the study was excellent. Patients were willing to visit the clinic and to complete the programme. Locally selected registered nurses with limited additional training were able to execute the programme and were comfortable with the protocol. Consequently, we believe the programme is feasible and practical and can be implemented into routine care. In addition, since the risk factors for atherosclerotic complications in other arterial territories are largely the same as in CAD, a similar approach may be considered for patients with cerebral and peripheral arterial disease.

Limitations

Some aspects of our trial warrant consideration. We excluded patients unable to attend the nurse clinics, and patients with a limited life expectancy. Potentially, this group of patients is older, sicker and less mobile than our study population. Possibly, patients with decreased mobility could benefit from other approaches, such as a telephonic nurse-coordinated prevention programme. However, this was not part of our investigation.

Our study population consisted of a slightly lower proportion of women as compared with other national and international surveys. In the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) III survey, performed in 22 countries in Europe (including the Netherlands), 27% of participants were women.³ In the Netherlands, 33% of all hospital admissions (88 765) for ischaemic heart disease in 2011 were in women.¹⁷

We excluded patients aged ≥ 80 years at the index event. Excluding these individuals lead to a slightly lower mean age (58 years) of our study population as compared with the mean age in other European cohorts of patients with ACS (eg, 62 years in EUROASPIRE III).³ The effects of a Nurse-coordinated prevention programme (NCP) in patients >80 years of age cannot be derived from our findings.

Our data on physical activity were self-reported. While we collected data on the duration and intensity of the physical activity, we did not assess cardiopulmonary fitness or exercise capacity. Potentially, a relevant increase in exercise capacity could also have occurred in patients who exercised less than 150 min per week.

CONCLUSION

The RESPONSE trial demonstrates that a nurse-coordinated hospital-based prevention programme with up to four outpatient clinic visits in addition to usual care results in sustained lowering of cardiovascular risk in patients with coronary disease. The programme was well attended, practical and can be

readily implemented into daily practice. In addition, our data suggest that the counselling component of the programme prevents unnecessary hospital readmissions.

Author affiliations

¹Department of Cardiology, Academic Medical Center—University of Amsterdam, Amsterdam, Noord Holland, The Netherlands

²Department of Cardiology, Medisch Spectrum Twente and University of Twente, Enschede, The Netherlands

³Department of Cardiology, Amphia Hospital, Breda, The Netherlands

⁴Department of Cardiology, Admiraal de Ruyter Hospitals, Goes, The Netherlands

⁵Department of Cardiology, Catharina Hospital, Eindhoven, The Netherlands

⁶Department of Cardiology, Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands

⁷Department of Cardiology, Deventer Hospital, Deventer, The Netherlands

⁸Department of Cardiology, Atrium Medical Center, Heerlen, The Netherlands

⁹Department of Cardiology, Medical Center Leeuwarden South, Leeuwarden, The Netherlands

¹⁰Department of Cardiology, Tergooi Hospitals, Hilversum, The Netherlands

¹¹Department of Cardiology, Reinier de Graaf Gasthuis, Delft, The Netherlands

Acknowledgements We would like to acknowledge the contribution of all the RESPONSE-nurses participating in the nurse-coordinated prevention programme: K Balhuizen, L Blom, J Doornbal, A van Drimmelen, H Helmes, I Kreemer, F Kuijper, R Lardinois, N Moerman, A Obbema, A Reijenga, I van Sleen, L van Stetten, A Klein Twennaar, E Wolf, D van der Woude.

Contributors All authors participated in the design and conduct of the trial. Acquisition of data: HTJ, CvonB, AMWA, AL, JMvanD, WJ, DJAL, HJAK, KdeV, PARdeM, AJAMW, RJGP. Analysis and interpretation of data: HTJ, JGPT, RJGP. Drafting of the manuscript: HTJ, JGPT, RJGP. Critical revision of the manuscript for important intellectual content: HTJ, CvonB, AMWA, AL, JMvanD, WJ, DJAL, HJAK, KdeV, PARdeM, AJAMW, WJMSopR, JGPT, RJGP. Statistical analysis: HTJ, JGPT, RJGP. Obtained funding: RJGP. Administrative, technical or material support: HTJ, CvonB, AMWA, AL, JMvanD, JW, DJAL, HJAK, KdeV, PARdeM, AJAMW, JGPT, RJGP. Study supervision: HTJ.

Funding The study was sponsored by an unrestricted grant from AstraZeneca, The Netherlands. The sponsor had no role in the design, data collection, data analysis, data interpretation and writing of this report.

Competing interests None.

Ethics approval The institutional committees on human research of all recruiting hospitals.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Requests for analyses of de-identified data from this trial should be directed to: HTJ (h.t.jorstad@amc.uva.nl).

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- 1 Smith SC, Allen J, Blair SN, *et al.* AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *Circulation* 2006;113:2363–72.
- 2 De Backer G, Ambrosioni E, Borch-Johnsen K, *et al.* European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). *Eur J Cardiovasc Prev Rehabil* 2003;10:S1–S10.
- 3 Kotseva K, Wood D, De Backer G, *et al.* EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. *Eur J Cardiovasc Prev Rehabil* 2009;16:121–37.
- 4 Murchie P, Campbell NC, Ritchie LD, *et al.* Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. *BMJ* 2003;326:84.
- 5 Wood DA, Kotseva K, Connolly S, *et al.* Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of

- cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet* 2008;371:1999–2012.
- 6 Allen JK, Dennison CR. Randomized trials of nursing interventions for secondary prevention in patients with coronary artery disease and heart failure: systematic review. *J Cardiovasc Nurs* 2010;25:207–20.
 - 7 Jørstad HT, Alings AMW, Liem AH, *et al.* RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse Specialists: Study design, objectives and expected results. *Neth Heart J* 2009;17:322–8.
 - 8 Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". *J Clin Epidemiol* 2001;54:217–24.
 - 9 Mccarney R, Warner J, Iliffe S, *et al.* The Hawthorne Effect: a randomised, controlled trial. *BMC Med Res Methodol* 2007;7:30.
 - 10 Revalidatiecommissie Nederlandse Hartstichting/Nederlandse Vereniging voor Cardiologie. *Richtlijn Hartrevalidatie*. Den Haag: Nederlandse Hartstichting, 2004.
 - 11 Burgers JS, Simoons ML, Hoes AW, *et al.* [Guideline 'Cardiovascular Risk Management']. *Ned Tijdschr Geneeskd* 2007;151:1068–74.
 - 12 Conroy RM, Pyörälä K, Fitzgerald AP, *et al.* Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987–1003.
 - 13 Wilson PW, D'Agostino RB, Levy D, *et al.* Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837–47.
 - 14 Bhatt DL, Eagle KA, Ohman EM, *et al.* Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. *JAMA* 2010;304:1350–7.
 - 15 D'Agostino RB, Russell MW, Huse DM, *et al.* Primary and subsequent coronary risk appraisal: new results from the Framingham study. *Am Heart J* 2000;139(2 Pt 1):272–81.
 - 16 Vernooij JWP, Kaasjager HAH, Van Der Graaf Y, *et al.* Internet based vascular risk factor management for patients with clinically manifest vascular disease: randomised controlled trial. *BMJ* 2012;344:e3750.
 - 17 Koopman C, Dis I, Bots M, *et al.* Hart- en vaatziekten in Nederland. In: Koopman C, van Dis I, Visseren FLJ, eds. *Hart- en vaatziekten in Nederland 2012, cijfers over risicofactoren, ziekte en sterfte*. Den Haag: Hartstichting, 2012:7–31.

Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial

Harald T Jorstad, Clemens von Birgelen, A Marco W Alings, et al.

Heart 2013 99: 1421-1430 originally published online June 28, 2013
doi: 10.1136/heartjnl-2013-303989

Updated information and services can be found at:

<http://heart.bmj.com/content/99/19/1421.full.html>

These include:

- References** This article cites 15 articles, 5 of which can be accessed free at:
<http://heart.bmj.com/content/99/19/1421.full.html#ref-list-1>
- Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>
- Email alerting service** Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
-

Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (88 articles)
[Drugs: cardiovascular system](#) (7484 articles)
[Epidemiology](#) (3006 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>